Creative Biolabs rAb Blog

Menu

Skip to content
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News

Category Archives: News

26Jun/19

Cancer Res: The Causes of Chemotherapy Resistance in Breast Cancer

June 26, 2019NewsBreast Cancer, Chemotherapy Resistancebiorab

According to a study recently published in Cancer Research by researchers and colleagues at the Belvich Institute of Biomedicine at the University of Barcelona, a large number of replicated chromosome regions areRead More…

17Apr/19

Scientists Found that Potassium Ions are the Key to Controlling the Anticancer Ability of T cells

April 17, 2019NewsCancer, Potassium Ion, T cellbiorab

A study led by scientists at the Center for Cancer Research (CCR) at the American National Cancer Institute (NCI) has revealed a way to promote the continued growth of tumors in theRead More…

19Feb/19

3D Bio-printing Model Changes Anti-cancer Drug Development and Anti-tumor Therapy

February 19, 2019News3D Model, Bio-printing, Cancerbiorab

Researchers at the University of Minnesota have developed a way to study cancer cells, which could lead to new and more effective treatments. They have developed a new method to study theseRead More…

01Feb/19

Nine characteristics shared by the most successful mAb

February 1, 2019News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody drug, therapeutic antibodybiorab

The path to finding a therapeutic antibody that leads to significant medical improvements is often complicated, long, and costly. Many criteria have to be taken into account in order to begin theRead More…

20Dec/18

Nat Genet:Scientists Discover New Target for Immunotherapy Following 2018 Nobel Prize for Medicine

December 20, 2018News, Therapeutic Antibody R&Dantibody discovery, immunotherapy, monoclonal antibody drug, therapeutic antibodybiorab

Following the 2018 Nobel Prize for Medicine, global attention is now more than ever turned toward the promise of immunotherapy in oncology. According to a recent study published in the international journalRead More…

27Sep/18

Antibody Combo Knocks Down HIV in Clinical Trials

September 27, 2018News, Therapeutic Antibody R&Dantibody combination, blocking antibody, hiv immunology, monoclonal antibody, monoclonal antibody drug, therapeutic antibodybiorab

A mix of two monoclonal antibodies against HIV tamped down virus levels in patients not taking antiretroviral medication, according to the results of two early-stage clinical trials reported in nature. After several infusionsRead More…

03Aug/18

Cancer Dis: Scientists Reveal New Mechanisms of Drug Resistance in Cancer Immunotherapy

August 3, 2018News, Therapeutic Antibody R&Dimmnunocheckpoint, Immune checkpoint therapy, monoclonal antibody drug, PD-1, pd-L1, therapeutic antibodybiorab

It is well known that the immune system can recognize and remove cancerous cells under normal conditions, but tumor cells will inhibit the immune system in the tumor development process, through differentRead More…

05Jul/18

Genetech’s New Drug Rituxan Approved for the Treatment of Serious Immune Diseases as a New Breakthrough during 60 Years

July 5, 2018News, Therapeutic Antibody R&Dimmune disesase, monoclonal antibody drug, pemphigus vulgaris, Rituximab, therapeutic antibodybiorab

A few days ago, Genentech, a Roche Group member, announced that the US FDA approved Rituxan® (rituximab) for the treatment of moderate to severe pemphigus vulgaris (PV). It is worth mentioning thatRead More…

29Jun/18

Scientists Found Key Factors Determining Anticancer Efficacy of Immune Checkpoint Therapy

June 29, 2018News, Therapeutic Antibody R&DFLT3LG, Immune checkpoint therapy, key factors, natural killer NK cell, PD-1, stimulating dendritic cellbiorab

Intratumoral stimulating dendritic cells (SDCs) play a key role in stimulating cytotoxic T lymphocytes and promoting immune responses against cancer. The study of mechanisms regulating the enrichment of SDCs in tumor microenvironmentRead More…

24May/18

Antibody Combo Expands Response to Checkpoint Inhibitor in Mice

May 24, 2018News, Recombinant Antibody R&D, Therapeutic Antibody R&Dantibody discovery, checkpoints, monoclonal antibody, monoclonal antibody drug, therapeutic antibodybiorab

Checkpoint inhibitor drugs, those that pull the brakes off the immune system, can cause dramatic improvements in cancer patients, but the benefits are far from universal. In the case of atezolizumab (Tecentriq),Read More…

Posts navigation

  • « Previous
  • 1
  • 2
  • 3
  • Next »

Categories

  • Antibody Engineering R&D
  • Cancer Immunotherapy
  • News
  • Recombinant Antibody R&D
  • Therapeutic Antibody R&D

Recent Posts

  • CD73 Inhibition: A Promising Strategy for Overcoming Immune Evasion in Colorectal Cancer
  • A Breakthrough in Influenza Defense: Discovering Antibodies for Broad-Spectrum Protection
  • Discovery of Highly Neutralizing Human Antibodies Targeting Pseudomonas aeruginosa for Treatment of Drug-Resistant Infections
  • Two New Strategies Targeting Siglec-7 Show Promise in Treating Ovarian Cancer
  • Researchers Revealed the Feasibility and Clinical Prospects of Targeting SLC7A11 for the Treatment of Osteosarcoma

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs rAb Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News